- Exchange: OTC US
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Neurobiological Technologies Inc
+ Add to WatchlistNTII:US
0.1200 USD 0.0100 9.09%As of 20:10:00 ET on 05/17/2013.
Snapshot for Neurobiological Technologies Inc (NTII)
| Open: | 0.1200 | Day's Range: | 0.1200 - 0.1200 | Volume: | 285 |
|---|---|---|---|---|---|
| Previous Close: | 0.1200 | 52wk Range: | 0.0880 - 0.2500 | 1-Yr Rtn: | +20.00% |
Key Statistics for NTII
| Current P/E Ratio (ttm) | 0.1622 |
|---|---|
| Estimated P/E(06/2010) | - |
| Relative P/E vs. SPX | 0.0099 |
| Earnings Per Share (ttm) | 0.7400 |
| Est. EPS (06/2010) | - |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 3.24 |
| Shares Outstanding (M) | 27.02 |
| 30 Day Average Volume | 6,109 |
| Price/Book (mrq) | 0.1392 |
| Price/Sale (ttm) | 0.1276 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend (USD) | 0.0500 |
| Last Dividend | 12/18/2012 |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | - |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for NTII
No data available
Company Profile & Key Executives for NTII
Neurobiological Technologies, Inc. (NTI) is a biopharmaceutical company focused on the clinical development and regulatory approval of neuroscience drugs. NTI is developing neuroprotective and neuromodulatory agents to treat progressive neurological impairments characteristic of various nervous system disorders, including diabetic neuropathy, brain cancer, and AIDS dementia syndrome.
| Matthew M LoarActing CEO/Acting CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
NTII News
-
Industry News
No stories found
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page